We demonstrate the key role of KIRREL in tumour progression and speculate that it might promote tumour cell proliferation and angiogenesis by activating the PI3K/AKT/mTOR pathway, revealing KIRREL as a potential target for GC therapy. Here, PIK3CA is linked to gastric cancer.